Slide 1: Life-Science Products: New Generation Pioneering
Life-Science Products NEW GENERATION PIONEERING OFER HAVIV | PRESIDENT & CEO May, 2024
Slide 2: Forward Looking Statement
2 FORWARD LOOKING STATEMENT This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd. (the “Company”), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding
Slide 3: Agenda
AGENDA Value Proposition Business Strategy Success Stories Summary 3 About Evogene
Slide 4: Desire for Progress & a Better Future
DESIRE FOR PROGRESS & A BETTER FUTURE HUMANS HAVE CONSISTENTLY INVESTED TIME AND RESOURCES IN THE PURSUIT OF IMPROVING LIFE, WELL-BEING, AND HEALTH, FUELED BY AN INNATE Throughout History 4
Slide 5: Our Vision
OUR VISION PIONEER GROUNDBREAKING LIFE-SCIENCE PRODUCTS ROOTED IN MICROBES, SMALL MOLECULES, AND GENOMICS DECODING BIOLOGY 5
Slide 6: Diverse Life-Science Industries
6 SMALL MOLECULES GENETIC ELEMENTS MICROBES AGRICULTURE & FOOD PHARMA & WELLNESS OTHER INDUSTRIES Plasticdegradation Chemicals Source forenzymes Oil spillclearing Waste-watertreatments Therapeuticmicrobials AGRICULTURE & FOOD PHARMA & WELLNESS OTHER INDUSTRIES Cropprotection Chemicalstimulants Pharm
Slide 7: The Complexity of Life Science Product Development
THE COMPLEXITY OF LIFE SCIENCE PRODUCT DEVELOPMENT Low probability of successwith high cost and long time-to market Pharma Industry Cost of developing a single pharmaceutical drug* In the 1970’s $180M In recent years $2,000M > Ag-chemicalsIndustry Years to develop a new crop protection product** 199
Slide 8: The Resource Killer: Life-Science Products Long-Tail Process
THE RESOURCE KILLER LIFE-SCIENCE PRODUCTS LONG-TAIL PROCESS > DISCOVERY > OPTIMIZATION > DEVELOPMENT > REGULATION THE CHALLENGE finding the winning candidates out of a vast number of possible prospects that address a complex myriad of criteria, to reach higher success rate for products “Needle in th
Slide 9: Today We Are on the Brink of a Historic Singularity Point
BIG DATA AI HISTORIC SINGULARITYPOINT TODAY WE ARE ON THE BRINK OF A Computational technology advancements enable the discovery and optimization of the most promising candidates, addressing multiple development challenges towards successful life-science based products LIFE-SCIENCE PRODUCT DEVELOPMEN
Slide 10: Our Mission
10 OUR MISSION AS PIONEERS AT THE FRONTIER, WE ARE DEDICATED TO REVOLUTIONIZING THIS FIELD. WE HARNESS CUTTING-EDGE COMPUTATIONAL BIOLOGY TECHNOLOGIES TO DRIVE PROGRESS, ENSURING OUR LEADERSHIP IN CREATING SOLUTIONS THAT PROPEL HUMANITY TOWARDS A BRIGHTER TOMORROW. DECODING BIOLOGY WE MERGE LIFE-SCI
Slide 11: When Life-Science Meets Disruptive Technologies
WHEN LIFE-SCIENCE MEETS DISRUPTIVE TECHNOLOGIES ISRAEL HQ EVGN NASDAQ & TASE Employees 4 Subsidiaries 3 Innovative AITech Engines PhD’s 2002 Established 50% Woman 11 COMMERCIAL PRODUCTS* Microbes Small Molecules Genetic Elements Microbiome-based Therapeutics Ag Biologicals Ag Chemicals Castor Cultiv
Slide 12: Commercial & Financial Partners
12 Group COMMERCIAL & FINANCIAL PARTNERS Investment & Collaboration Collaboration Investment & Collaboration Collaboration Collaboration Investment Collaboration Collaboration Collaboration Collaboration Collaboration
Slide 13: Agenda
AGENDA Value Proposition Business Strategy Success Stories Summary 13 About Evogene
Slide 14: Our Solution: Computational Predictive Biology Platform
BIG DATA SCIENCE AI OUR SOLUTION Born from over a decade of intensive R&D, fueled by millions of dollars in investment, merging life-science with big- data and cutting-edge AI technology, the CPB directs and accelerates life-science product discovery and optimization through dedicated AI Tech-Engine
Slide 15: Discovery & Optimization with 3 AI Tech-Engines
DISCOVERY & OPTIMIZATION WE DIRECT AND ACCELERATE LIFE-SCIENCE PRODUCT utilizing 3 dedicated AI tech-engines MICROBES GENETIC ELEMENTS SMALL MOLECULES The Result: Promising candidates addressing multiple development challenges towards successful life-science-based products. PROBABILITY OF SUCCESS TI
Slide 16: AI Tech-Engines
16 AI TECH-ENGINES Direct & accelerate life-science product discovery & optimization Computational selection of the most promising candidates to initiate the product development process. Computational driven solution addressing optimization challenges for the selected candidates, without impairing t
Slide 17: AI Tech-Engine Dashboard (Example)
AI TECH-ENGINEDASHBOARD(Example) 17
Slide 18: Potential Market Diversity
AGRICULTURE & FOOD PHARMA & WELLNESS OTHER INDUSTRIES 18 POTENTIAL MARKET DIVERSITY Structuring an ’ecosystem’ of diverse product types to be developed utilizing our AI Tech-Engines Potential Markets for MicroBoost AI (Example) Plasticdegradation Chemicals Source forenzymes Oil spillclearing Waste-w
Slide 19: Agenda
AGENDA Value Proposition Business Strategy Success Stories Summary 19 About Evogene
Slide 20: A World of Opportunities for Our AI Tech Engines
20 SMALL MOLECULES GENETIC ELEMENTS MICROBES A WORLD OF OPPORTUNITIES FOR OUR AI TECH ENGINES AGRICULTURE & FOOD PHARMA & WELLNESS OTHER INDUSTRIES Improvedcrops Alternativefood Medical Cannabis Genetherapy Diagnostics & precisionmedicine Celltherapy Bio fuel Fragrances Natural foodcoloring Novelenz
Slide 21: Business Strategy
21 BUSINESS STRATEGY Capture the value of our AI tech-engines through diverse collaborative partnerships to accelerate life-science product development Partnering with experts in specific fields complements our technology, enabling groundbreaking innovations and financial gains for Evogene. EVOGENE
Slide 22: Business Model: Two Main Partnership Structures
22 BUSINESS MODEL Two Main Partnership Structures Joint product development with a leading company utilizing Evogene’s unique tech-engines. Typically, the partner leads later-stage development and product commercialization. COLLABORATION A time-limited license grant for utilizing one of Evogene’s te
Slide 23: Licensing: Potential Revenue Stream
23 01 Licensing Potential revenue stream License fees & R&D reimbursement Royalties from sale of end-products Dividends to Evogene as a shareholder* Significant one-time-payment upon an exit event** Powered by Business Model *Subject to meeting the Israeli dividend tests and criteria. May no be dist
Slide 24: Collaboration: Potential Revenue Stream
24 02 Business Model Collaboration Powered by Potential revenue stream Upfront payments R&D fees Milestone payments Royalties from sale of end-products
Slide 25: Licensing & Collaboration | Current Status
Aquaculture Crustacean gene editing Food-tech Protein production in Plants for food-tech Crop protection Herbicides Fungicides Insecticides Licensing Collaboration Improved traits - canola Microbials for crops Therapeutic microbials 25 LICENSING & COLLABORATION | CURRENT STATUS SMALL MOLECULES GENET
Slide 26: Agenda
AGENDA Value Proposition Business Strategy Success Stories Summary 26 About Evogene
Slide 27: Ag-Biologicals: A Rapidly Growing Market
AG-BIOLOGICALS A RAPIDLY GROWINGMARKET UNIQUE AI TECH-PLATFORM AND DATA ASSETS BROAD &DIVERSEPIPELINE 8 programs under development;new product launch expected every 1-2 years Proprietary tech platform increases probability of success and reduces cost and time-to-market The ag-biologicals market is e
Slide 28: Yalos Bio-inoculant for Cereal Grains
Powered by Yalos™ | Bio-inoculant for cereal grains* 28 SOLD IN USA & CANADA**& expanding globally SUPERIOR PERFORMANCEvs. alternatives CONSISTENT PERFORMANCE 2% 1% 3% 4% 6% Other Ag-biologicals Control Yield improvement (%) 5% Check Evogene’s Subsidiary * Yalos™ has regulatory approval in the US &
Slide 29: MicroBoost AI Tech-Engine
Powered by MICROBOOST AI TECH-ENGINE 29 directing & accelerating product discovery & optimization Computational analysis of DB ~100,000 Bacterialstrains 1000 Predicted bacterial strains 50 Validated bacterialstrains 5-10 Predicted teams Powered by Experimental validation 5% success Commercial viabil
Slide 30: Castor Oil - Emerging Market Integrated Ag-Solution
CASTOR OIL - EMERGING MARKET INTEGRATED AG-SOLUTION COMMERCIAL PRODUCTS Proprietary varieties with improved traits suitable for commercial scale cultivation EVF716, EVF712, EVF701 Elite varieties suitable for mechanized farming, growing protocols, mechanized harvesting and dehulling solutions A sust
Slide 31: Elite Castor Varieties
Powered by Evogene’s Subsidiary EVF716, EVF712, EVF701 31 Elite Castor Varieties $9.1 Million
Slide 32: Generator AI Tech Engine
EVF701 EVF712 EVF716 Powered by 32 GENERATOR AI TECH ENGINE directing & accelerating product discovery & optimization Genetic diversity ~200 * WW germplasm accessions >10,000 Lines 800 Lines w/ high yield & oil potential 150 Advanced lines High-throughput field trials for elite varieties Breeding pr
Slide 33: Agenda
AGENDA Value Proposition Business Strategy Success Stories Summary 33 About Evogene
Slide 34: Summary: Vision, Mission, Business Strategy, Offering
VISION Pioneer groundbreaking life-science products rooted in microbe, small molecule, and genomics innovations. We merge scientific expertise with cutting-edge AI and big data technologies to discover and optimize innovative life-science products effectively. MISSION BUSINESS STRATEGY MAXIMUM POTEN
Slide 35: Thank You
THANK YOU
Slide 36: Annex I: Financial Overview
Annex I FINANCIAL OVERVIEW 36
Slide 37: Key Financials: Balance Sheet
Thousands of US $ 31.03.2024 31.12.2023 Current Assets 31,022 34,469 Long-Term Assets 15,758 16,632 Total Assets 46,780 51,101 Current Liabilities 6,129 6,944 Long-Term Liabilities (inc. ~$10m convertible SAFE at Lavie Bio) 15,268 15,472 Equity attributable to equity holders of the Company 8,289 12,
Slide 38: Key Financials: Q1 2024 Results
KEY FINANCIALS: BALANCE SHEET 38 Key Points: Q1 2024 revenue: $4.2M vs. $0.6M in Q1 2023; anticipating continued growth in 2024. Q1 2024 net loss: $3.8M vs. $7.0M in Q1 2023. Projected 2024 cash usage, excluding Lavie Bio and Biomica: $8.0M, down 36% from $12.5M in 2023. Thousands of US $ 1-3/2024 1
Slide 39: Annex II: Evogene Subsidiaries
Annex II EVOGENE SUBSIDIARIES
Slide 40: Castor Oil Production: Casterra
CASTOR OIL PRODUCTION CASTERRA’S MISSION: To provide an integrated solution for industrial cultivation of castor for bio-based industries BACK 2008 6 >3000 >1000MT Established Production sites Seed lines HQR&D Expected Value Drivers Expanding the seed production operations in several sites in Africa
Slide 41: Ag Biologicals: Lavie Bio
Ag Biologicals LAVIE BIO’S MISSION: Improve food quality, sustainability and agriculture productivity through microbiome based, AI-driven, ag-biological products 2019 25 1 7 Established Employees Commercial product Products in development BIO-STIMULANTS Yalos™ – distribution licensing agreements and
Slide 42: Human Microbiome: Biomica
Human Microbiome BIOMICA’S MISSION: Discovery and development of novel microbiome-based therapeutics for human disorders, utilizing cutting edge computational capabilities 2017 20 3 1 $20M Established Employees Programs - clinical /preclinical stage Leading program - phase 1 Recent financing round E
Slide 43: Ag-Chemicals: AgPlenus
AG-CHEMICALS AGPLENUS’ MISSION: Design next-generation, effective, and sustainable crop protection products by leveraging predictive chemistry and biology 2018 13 5 3 Established Employees Programs under development Programs under collaboration HQR&D Expected Value Drivers HERBICIDES Corteva collabo